Evidence map›Paper›PMID 27104867›Full record

ArticleCancer biology & therapy2016

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Yu Sunakawa, Dongyun Yang, Miriana Moran, Stephanie H Astrow, Akihito Tsuji, Craig Stephens, Wu Zhang, Shu Cao, Takehiro Takahashi, Tadamichi Denda and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 2 countries.

Yu Sunakawaa Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA.
Dongyun Yangc Department of Preventive Medicine , Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA.
Miriana Morand Response Genetics, Inc. , Los Angeles , CA , USA.
Stephanie H Astrowd Response Genetics, Inc. , Los Angeles , CA , USA.
Akihito Tsujie Department of Clinical Oncology , Kagawa University Faculty of Medicine Cancer Center, Kagawa University Hospital , Kita-gun , Kagawa , Japan.
Craig Stephensd Response Genetics, Inc. , Los Angeles , CA , USA.
Wu Zhanga Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA.
Shu Caoc Department of Preventive Medicine , Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA.
Takehiro Takahashif Division of Medical Oncology, Showa University Hospital , Shinagawa-ku, Tokyo , Japan.
Tadamichi Dendag Division of Gastroenterology, Chiba Cancer Center , Chuo-ku, Chiba , Japan.
Ken Shimadah Division of Medical Oncology, Department of Internal Medicine, Showa University Koto Hospital , Toyosu, Koto-ku, Tokyo , Japan.
Mitsugu Kochii Department of Digestive Surgery , Nihon University School of Medicine , Itabashi-ku, Tokyo , Japan.
Masato Nakamuraj Aizawa Comprehensive Cancer Center, Aizawa Hospital , Matsumoto , Nagano , Japan.
Masahito Kotakak Gastrointestinal Center, Sano Hospital , Kobe , Hyogo , Japan.
Yoshihiko Segawal Division of Medical Oncology, Saitama Medical University International Medical Center , Hidaka , Saitama , Japan.
Toshiki Masuishim Division of Gastroenterology, Tsuchiura Kyodo General Hospital , Tsuchiura , Ibaraki , Japan.
Masahiro Takeuchin Department of Clinical Medicine (Biostatistics) , Kitasato University School of Pharmacy , Shirokane, Minato-ku, Tokyo , Japan.
Masashi Fujiii Department of Digestive Surgery , Nihon University School of Medicine , Itabashi-ku, Tokyo , Japan.
Toshifusa Nakajimao Japan Clinical Cancer Research Organization , Chuo-ku, Tokyo , Japan.
Wataru Ichikawap Division of Medical Oncology, Showa University Fujigaoka Hospital , Yokohama , Kanagawa , Japan.
Heinz-Josef Lenza Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA.
University of Southern California · USNihon University · JPAizawa Hospital · JPChiba Cancer Center · JPJapan Clinical Cancer Research Organization · JPKagawa University Hospital · JPKitasato University · JPSaitama Medical University · JPShowa University · JPShowa University Fujigaoka Hospital · JPShowa University Hospital · JPTsuchiura Kyodo General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several studies have reported that epidermal growth factor receptor (EGFR)-related molecules may serve as predictors of cetuximab treatment for metastatic colorectal cancer (mCRC), such as EGFR gene copy number (GCN), expression of 2 ligands of EGFR, amphiregulin (AREG) and epiregulin (EREG), and EGFR CA simple sequence repeat 1 (CA-SSR1) polymorphism; however, these biomarkers still remain not useful in clinical practice since they have been evaluated using cohorts with patients treated in various settings of chemotherapy. We therefore analyzed associations of mRNA expression of AREG and EREG, EGFR GCN, and CA-SSR1 polymorphism [short (S;≤ 19) / long (L; ≥ 20)] with clinical outcomes in 77 Japanese patients with KRAS exon 2 wild-type mCRC enrolled in phase II trials of FOLFOX (n = 28/57, UMIN000004197) or SOX (n = 49/67, UMIN000007022) plus cetuximab as first-line therapy. High AREG expression correlated with significantly better progression-free survival (median 11.6 vs. 66 months, HR 0.52, P = 0.037); moreover, it remained statistically significant in multivariate analysis (HR: 0.48, P = 0.027). S/S genotype of CA-SSR1 predicted severe skin toxicity (P = 0.040). Patients with both AREG-low and EGFR low-GCN had significantly shorter overall survival than the others (median 22.2 vs. 42.8 months, HR 2.34, P = 0.042). The multivariate analysis showed that molecular status with both AREG-low and EGFR low-GCN was a predictor of worse survival (P = 0.006). In conclusion, AREG mRNA expression and EGFR CA-SSR1 polymorphism predict survival and skin toxicity, respectively, of initial chemotherapy with cetuximab. Our results also suggest potential prognostic value of the combined assessment of AREG and EGFR GCN for first-line cetuximab treatment.

Indexed as

AdultAgedAntineoplastic AgentsCetuximabColorectal NeoplasmsErbB ReceptorsFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisTreatment OutcomeAntineoplastic AgentsCetuximabErbB ReceptorsAmphiregulincetuximabcolorectal cancerEGFREGFR gene copy number

Identifiers

PMID27104867
PMCPMC4970538
OpenAlexW2336217205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.